Summary of results from the European Randomized Study of Screening for Prostate Cancer (ERSPC) after 9–16 years of follow-up
| Median follow-up (years) | 9 | 11 | 13 | 16 |
| Positive predictive value of biopsy (%) | 24.1 | 24.2 | 24.2 | 24.2 |
| PCa diagnosed in screening group (No) | 5990 | 6963 | 7408 | 8444 |
| PCa diagnosed in control group (No) | 4307 | 5396 | 6107 | 7732 |
| Excess PCa incidence per 1000 men | 34 | 35 | 35 | 30 |
| Relative PCa mortality reduction (%) | 20 | 21 | 21 | 20 |
| Absolute PCa mortality reduction per 1000 men | 0.71 | 1.07 | 1.28 | 1.76 |
| Reference number | 22 | 23 | 24 | 6 |
PCa, prostate cancer.